Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Yannick Le Bris, Barbara Burroni, Marguerite Fournier, Morgane Cheminant, Sara Ek, Eva Hoster, Marie-Helene Delfau-Larue, Clémentine Sarkozy, Mary B. Callanan, Benoit Tessoulin, David Chiron, Martin Dreyling, Mats Jerkeman, Steven Le Gouill, Olivier Hermine

Blood (2024) 144 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2024-199152

Published: 2024

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms

Yannick LE Bris, Romain Madeuf, Catherine Godon, Olivier Pichon, Pierre Peterlin, Alice Garnier, Patrice Chevallier, Simon Bouzy, Marion Eveillard, Marie-Christine Béné, Olivier Theisen, Faeseh vasheghani Farahani

Blood (2023) 142 (Supplement 1): 6051.

https://doi.org/10.1182/blood-2023-188581

Published: 2023

Journal Articles

Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening

Blood (2023) 142 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2023-186874

Published: 2023

Journal Articles

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Blood (2023) 142 (Supplement 1): 6107.

https://doi.org/10.1182/blood-2023-173815

Published: 2023

Journal Articles

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Blood (2023) 142 (18): 1543–1555.

https://doi.org/10.1182/blood.2023020211

Published: 2023

Includes: Supplemental data

Journal Articles

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Blood (2023) 141 (11): 1353–1358.

https://doi.org/10.1182/blood.2022017755

Published: 2023

Includes: Supplemental data

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening

Cedric De almeida Braga, Maxence Bauvais, Maxence Dominici, Alice Garnier, Pierre Peterlin, Camille Debord, Soraya Wuillème, Olivier Theisen, Catherine Godon, Simon Bouzy, Yannick Le Bris, Marie C Bene, Patrice Chevallier, Nicolas Normand, Marion Eveillard

Blood (2022) 140 (Supplement 1): 9800–9801.

https://doi.org/10.1182/blood-2022-166979

Published: 2022

Journal Articles

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Blood (2022) 140 (Supplement 1): 9821–9823.

https://doi.org/10.1182/blood-2022-162278

Published: 2022

Journal Articles

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Salomé Decombis, Celine Bellanger, Yannick Le Bris, Delphine Boulet, Jane Jardine, Christelle Dousset, Audrey Ménard, Charlotte Kervoelen, Elise Douillard, Philippe Moreau, Stephane Minvielle, Agnes Moreau-Aubry, Benoit Tessoulin, Nicolas Bidère, Steven Le Gouill, Catherine Pellat-Deceunynck, David Chiron

Blood (2022) 140 (Supplement 1): 2044–2045.

https://doi.org/10.1182/blood-2022-157694

Published: 2022

Journal Articles

Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma

Baptiste Le Calvez, Yannick Le Bris, Thomas Gastinne, Viviane Dubruille, Béatrice Mahé, Nicolas Blin, Anne Lok, Sophie Vantyghem, Clara Sortais, Cyrille Touzeau, Steven Le Gouill, Philippe Moreau, Patrice Chevallier, Marion Eveillard, Marie C Bene, Benoit Tessoulin

Blood (2022) 140 (Supplement 1): 12766–12767.

https://doi.org/10.1182/blood-2022-170113

Published: 2022

Journal Articles

Vexas Syndrome: A Complex Necessarily Integrated Diagnosis That Can Benefit from the Help of Deep Learning

Cedric De almeida Braga, Camille Richard, Baptiste Le Calvez, Patrice Chevallier, Simon Bouzy, Yannick Le Bris, Alice Garnier, Pierre Peterlin, Marie C Béné, Nicolas Normand, Marion Eveillard

Blood (2022) 140 (Supplement 1): 13025–13026.

https://doi.org/10.1182/blood-2022-169059

Published: 2022

Journal Articles

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Blood (2022) 140 (7): 756–768.

https://doi.org/10.1182/blood.2021015328

Published: 2022

Includes: Supplemental data

Journal Articles

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Patrice Chevallier, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Yannick Le Bris, Marion Eveillard, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Anne Lok, Cyrille Touzeau, Thomas Gastinne, Benoit Tessoulin, Maxime Jullien, Sophie Vantyghem, Philippe Moreau, Steven Le Gouill, Marie C Bene, Thierry Guillaume

Blood (2021) 138 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2021-149534

Published: 2021

Journal Articles

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

Stephanie Dulucq, Frédéric Bauduer, Jean-Michel Cayuela, Patrice Chevallier, Pascale Cony-Makhoul, Yannick Le Bris, Laurence Legros, Herve Maisonneuve, Lydia Roy, Francois-Xavier Mahon, Sandrine Hayette, Delphine Rea, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 2556.

https://doi.org/10.1182/blood-2021-149986

Published: 2021

Journal Articles

Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy

Blood (2021) 138 (Supplement 1): 3465.

https://doi.org/10.1182/blood-2021-149405

Published: 2021

Journal Articles

Single Capture High Throughput Sequencing Assay for Combined V(D)J Clonality Analysis and Oncogene Mutations in the Diagnosis of T and B Lymphoid Malignancies

Yannick Le Bris, Audrey Ménard, Anne Moreau, Nowenn Le Lan, Céline Bossard, Marie C Béné

Blood (2021) 138 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2021-151083

Published: 2021

Journal Articles

Comprehensive Analysis of the Tumoral and Microenvironmental Transcriptome of Lymph Nodes and Bone Marrow in Mantle Cell Lymphoma

Yannick Le Bris, Anne Moreau, Audrey Ménard, Louise Bouard, Adeline Normand, Bruno Villemagne, Steven Le Gouill, Marie C Bene

Blood (2021) 138 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2021-151041

Published: 2021

Journal Articles

CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

Pierre Peterlin, Pascal Turlure, Patrice Chevallier, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Anna Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose Miguel Torregrosa Diaz, Louis Devron, Sylvie Chevret, Marie C Bene, Yannick Le Bris, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Pierre Fenaux

Blood (2021) 138 (Supplement 1): 243.

https://doi.org/10.1182/blood-2021-145123

Published: 2021

NARROW

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms

Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma

Vexas Syndrome: A Complex Necessarily Integrated Diagnosis That Can Benefit from the Help of Deep Learning

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy

Single Capture High Throughput Sequencing Assay for Combined V(D)J Clonality Analysis and Oncogene Mutations in the Diagnosis of T and B Lymphoid Malignancies

Comprehensive Analysis of the Tumoral and Microenvironmental Transcriptome of Lymph Nodes and Bone Marrow in Mantle Cell Lymphoma

CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only